Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

Our mission is to develop and commercialize novel therapeutics to treat rare seizure disorders and other chemical imbalance disorders, as well as to provide personalized and compassionate care for patients and their families.

Our vision is to provide premier medical care for patients and their families and deliver state-of-the-art science-based therapies.

Marinus has received several awards, including the 2015 National Institutes of Health Director’s Patent Award and the 2016 Enduring Impact Award from the American Epilepsy Society.